Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
Public ClinicalTrials.gov record NCT04233073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Open-Label Clinical Study of Andexanet Alfa in Patients Receiving FXa (Activated Factor X) Inhibitor Who Require Urgent Surgery
Study identification
- NCT ID
- NCT04233073
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- andexanet alfa Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 84 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2021
- Primary completion
- Nov 22, 2021
- Completion
- Jan 24, 2022
- Last update posted
- Mar 21, 2023
2021 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Phoenix | Arizona | 85006 | — |
| Clinical Trial Site | Tucson | Arizona | 85724 | — |
| Clinical Trial Site | Long Beach | California | 90806 | — |
| Clinical Trial Site | Moreno Valley | California | 92555 | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20037 | — |
| Clinical Trial Site | Sarasota | Florida | 34239 | — |
| Clinical Trial Site | Tampa | Florida | 33606 | — |
| Clinical Trial Site | Iowa City | Iowa | 52242 | — |
| Clinical Trial Site | Boston | Massachusetts | 02111 | — |
| Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| Clinical Trial Site | Camden | New Jersey | 08103 | — |
| Clinical Trial Site | Staten Island | New York | 10305 | — |
| Clinical Trial Site | Charlotte | North Carolina | 28203 | — |
| Clinical Trial Site | Durham | North Carolina | 27710 | — |
| Clinical Trial Site | Columbus | Ohio | 43210 | — |
| Clinical Trial Site | Tulsa | Oklahoma | 74104 | — |
| Clinical Trial Site | Portland | Oregon | 97239 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15212 | — |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04233073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2023 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04233073 live on ClinicalTrials.gov.